This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Thrombolysis  • Cardiovascular System  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

I have recently read "Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations by Hirsh and Bhatt.¹ I chose to compare those lessons learned with a relevant chapter in the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy.²

In their article, Hirsh and Bhatt¹ review the Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial data and conclude that, compared with aspirin, clopidogrel is superior in outcomes in subsets of patients (those with history of coronary artery bypass grafting, history of >1 ischemic event, involvement of multiple vascular beds, diabetes, and hypercholesterolemia) without any statistical conclusion of difference noted. Does not the lack of statistical evidence of difference make it impossible to support any conclusion of difference?

Of the subgroups prospectively identified by the CAPRIE trialists, the subgroup of patients with stroke and the subgroup with myocardial infarction showed no significant difference . . . [Full Text of this Article]

AUTHOR INFORMATION
Donald B. Hansen, PharmD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?